4-Iodo-SAHA (1k), an orally active inhibitor of both class I and class II histone deacetylase (HDAC), exhibits EC50 values of 1.1, 0.95, 0.12, 0.24, 0.85, and 1.3 μM for Skbr3, HT29, U937, JA16, and HL60 cell lines, respectively. This compound holds potential for cancer research purposes [1].

4-Iodo-SAHA (1k) demonstrates inhibitory effects on several cell lines including Skbr3, HT29, U937, JA16, and HL60 at concentrations ranging from 0.1-100 μM over 48 hours, according to study findings. Particularly in SKBR3 cells, exposure to 2 μM of 4-Iodo-SAHA for periods between 6-24 hours results in increased levels of acetylated H4 and p21. A Cell Proliferation Assay reveals that the compound successfully inhibits the growth of SKBR3, HT29, U937, JA16, and HL60 cell lines with EC50 values of 1.1, 0.95, 0.12, 0.24, 0.85, and 1.3 μM, respectively, indicating its 10-fold increased potency against the U937 cell line when compared to SAHA. Western Blot Analysis further corroborates these findings by showing a time-dependent increase in histone H4 acetylation and p21/WAF1 cell cycle inhibitor in SKBR3 cells, outlining 4-Iodo-SAHA's efficacy as both an inhibitor of cell proliferation and a modulator of cellular mechanisms related to acetylation and cell cycle regulation.

4-Iodo-SAHA (1k) administered orally at a dosage of 50 mg/kg five times a week for two weeks exhibited comparable toxicity levels to those observed in SAHA-treated and control mice, as demonstrated by similar body weights and hematological counts in 8-week-old fvb mice [1].